Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 771 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable... April 12, 2022 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 NCI Part of Federal Effort to Evaluate Antibody Tests for Novel... May 5, 2020 Load more HOT NEWS Patient Guide on Bone Health in Cancer Now Available Also in French 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,...
